propafenone has been researched along with quinidine in 95 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 25 (26.32) | 18.7374 |
1990's | 29 (30.53) | 18.2507 |
2000's | 28 (29.47) | 29.6817 |
2010's | 9 (9.47) | 24.3611 |
2020's | 4 (4.21) | 2.80 |
Authors | Studies |
---|---|
Topliss, JG; Yoshida, F | 1 |
Gao, F; Lombardo, F; Shalaeva, MY; Tupper, KA | 1 |
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 2 |
Pajeva, IK; Wiese, M | 1 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
Adrián, F; Anderson, P; Brinker, A; Caldwell, JS; Chatterjee, A; Gray, NS; Henson, K; Janes, J; Kato, N; Kuhen, K; Matzen, JT; McNamara, C; Nagle, A; Nam, TG; Plouffe, D; Schultz, PG; Trager, R; Winzeler, EA; Yan, SF; Zhou, Y | 1 |
Alimuddin, M; Bulloch, D; Dahl, R; Grant, D; Lee, N; Peacock, M | 1 |
Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
Cooper, J; Cui, Y; Fink, M; Gavaghan, DJ; Heath, BM; McMahon, NC; Mirams, GR; Noble, D; Sher, A | 1 |
Caradonna, NP; Hallifax, D; Houston, JB; Turlizzi, E; Zanelli, U | 1 |
Barnes, SW; Bonamy, GM; Bopp, SE; Borboa, R; Bright, AT; Chatterjee, A; Che, J; Cohen, S; Dharia, NV; Diagana, TT; Fidock, DA; Froissard, P; Gagaring, K; Gettayacamin, M; Glynne, RJ; Gordon, P; Groessl, T; Kato, N; Kuhen, KL; Lee, MC; Mazier, D; McNamara, CW; Meister, S; Nagle, A; Nam, TG; Plouffe, DM; Richmond, W; Roland, J; Rottmann, M; Sattabongkot, J; Schultz, PG; Tuntland, T; Walker, JR; Winzeler, EA; Wu, T; Zhou, B; Zhou, Y | 1 |
Fijorek, K; Glinka, A; Mendyk, A; Polak, S; Wiśniowska, B | 1 |
Dalvie, D; Loi, CM; Smith, DA | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Bellman, K; Knegtel, RM; Settimo, L | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Arnold, E; De Clercq, E; Fang, Z; Feng, D; Kang, D; Liu, X; Pannecouque, C; Pilch, A; Ruiz, FX; Sun, Y; Wang, Z; Wei, F; Zhan, P; Zhao, T | 1 |
Bertagnin, C; Du, R; Guizzo, L; Hou, L; Huang, B; Jia, R; Ju, H; Kang, D; Kong, X; Li, P; Liu, X; Loregian, A; Ma, X; Murugan, NA; Poongavanam, V; Zhan, P; Zhang, Y | 1 |
Castro, I; de Brito, FS; Maia, IG; Pereira, MH | 1 |
Baĭer, T; Brakhmann, I; Khilbel, T; Kiubler, V; Shmitt, K; Valdeker, B | 1 |
Lu, F; Mei, BY; Zhang, XM | 1 |
Deiwick, M; Konertz, W; Scheld, HH; Weyand, M | 1 |
Brusca, A; Comba Costa, G; Gaita, F; Gaschino, G; Greco, C; Richiardi, E; Rosettani, E | 1 |
Benz, I; Kohlhardt, M | 2 |
Hansen, JF; Madsen, JK; Nielsen, H; Rasmussen, V; Sørum, C | 1 |
Gillis, AM; Keashly, R | 1 |
Cohen, JM; Gillis, AM; Hii, JT; Mitchell, LB; Wyse, DG | 1 |
Bauernfeind, RA; Welch, WJ | 1 |
Grant, AO; Starmer, CF | 1 |
Funck-Brentano, C; Kroemer, HK; Pavlou, H; Roden, DM; Woosley, RL | 1 |
Bobbio, M; Bocchiardo, M; Gaita, F; Uslenghi, E; Vado, A | 1 |
Somberg, J | 1 |
Roden, DM; Siddoway, LA; Woosley, RL | 1 |
Amiel, A; Boutaud, P; Ciber, M; Demange, J; Guillem, JP; Herpin, D; Maarek-Charbit, M | 1 |
Huang, SK; Marcus, FI | 1 |
Allessie, MA; Bonke, FI; Lammers, WJ; Rensma, PL; Schalij, MJ | 1 |
Fenster, PE; Horwitz, L; Huang, SK; Kirsten, EB; Klein, RC; Marcus, FI; Rushforth, N | 1 |
Alboni, P; Candini, GC; Cappato, R; Paparella, N; Pirani, R | 1 |
Baker, BJ; deSoyza, N; Dinh, HA; Franciosa, JA; Murphy, ML | 1 |
Hirosawa, K; Kasanuki, H; Onishi, S | 1 |
Podrid, PJ | 1 |
Atarashi, H; Hayakawa, H | 1 |
Graboys, TB; Lampert, S; Lown, B; Podrid, PJ | 1 |
Schmitz, W | 1 |
Attuel, P; Coumel, P; Georgiopoulos, G; Halkidis, H; Leclercq, JF; Maisonblanche, P | 1 |
Somberg, JC | 1 |
Ceci, V; Di Marcotullio, G; Dini, P; Milazzotto, F; Polizzi, C; Santini, M | 1 |
Accettura, D; De Nicolò, M; De Toma, L; Lagioia, R; Mangini, SG; Rizzon, P; Scrutinio, D | 1 |
Assayag, P; Coumel, P; Leclercq, JF | 1 |
De Nicolò, M; De Toma, L; Lagioia, R; Mangini, SG; Rizzon, P; Scrutinio, D | 1 |
Ledda, F; Mantelli, L; Manzini, S; Mugelli, A | 1 |
Grey, E; Silverman, DI | 1 |
Bachernegg, M; Decrinis, M; Domanowits, H; Kickenweiz, E; Laggner, AN; Stark, G; Stark, U; Sterz, F; Tritthart, HA | 1 |
Fernández del Pozo, B; Pérez-Vizcaíno, F; Tamargo, J; Zaragozá, F | 1 |
Mörike, KE; Roden, DM | 1 |
Castle, NA; Slawsky, MT | 1 |
Boriani, G; Capucci, A; Della Casa, S; Magnani, B; Rubino, I; Sanguinetti, M | 1 |
Cowan, JC | 1 |
Lüderitz, B; Manz, M | 1 |
Brechenmacher, C; Chauvin, M; Koenig, A; Theolade, R | 1 |
Ebner, T; Eichelbaum, M | 1 |
Roden, DM | 1 |
Arrigo, F; Cavallaro, L; Coglitore, A; Fazio, F; Oreto, G; Saporito, F; Satullo, G; Sorrenti, S | 1 |
Chang, MS; Chen, SA; Chiang, CE; Lee, SH; Tai, CT; Wang, SP; Wen, ZC | 1 |
Di Benedetto, S | 1 |
Beurrier, D; Brembilla-Perrot, B; Danchin, N; Houplon, P; Jacquemin, L; Louis, P; Terrier de la Chaise, A | 1 |
Bellandi, F; Cantini, F; Dabizzi, RP; Mugnaioni, G; Palchetti, R | 1 |
Capucci, A | 1 |
Epstein, LM; Huang, DT; Josephson, ME; Monahan, KM; Papageorgiou, P; Zimetbaum, P | 1 |
Aschieri, D; Capucci, A; Piepoli, M; Villani, GQ | 1 |
Dell'Orfano, JT; Luck, JC; Naccarelli, GV; Patel, HM; Wolbrette, DL | 1 |
Ishii, K; Kubota, Y; Moriuchi, H; Nakahara, T; Sakamato, K; Shigenobu, K; Tanaka, Y; Yunoki, M | 1 |
Chow, MS; Fan, C; Lau, CP; Tang, MO; Tse, HF | 1 |
Hancox, JC; Paul, AA; Witchel, HJ | 1 |
Bhatta, L; Hynes, J; Khan, M; Luck, J; Naccarelli, GV; Samii, S; Wolbrette, DL | 1 |
Kao, W; Kowey, PR; Winkel, E; Yan, GX | 1 |
Furuichi, K; Inamura, K; Kitada, C; Matsushime, H; Miyake, A; Mochizuki, S; Nozawa, K; Okada, H; Sano, Y; Yokoi, H | 1 |
BORIS, A; MOE, RA; SCHALLEK, WE | 1 |
Borbély, M; Dani, G; Erdej, F; Hajdara, I; Katona, A; Márk, L; Nagy, E; Sziklai, G | 1 |
Dorian, P; Humphries, KH; Kerr, CR; Steinbuch, M | 1 |
Amor, F; Charisius, M; Plass, H; Turnheim, K; Wiener, H; Wyskovsky, W | 1 |
Iwaki, M; Komura, H | 1 |
Scharf, C | 1 |
Bakula, M; Frank, B; Gavranovic, Z; Milicevic, G; Pazur, V | 1 |
Daubert, JP | 1 |
Kochanowski, J; Kosior, DA; Opolski, G; Piatkowski, R; Postuła, M; Rabczenko, D; Scisło, P | 1 |
Champagne, J; Charbonneau, L; Geelen, P; Gilbert, M; Hamelin, BA; Michaud, V; O'Hara, GE; Philippon, F; Pruneau, G; Turgeon, J | 1 |
Bai, J; Gao, M; Lo, A; Lu, Y; Zhang, H; Zhao, J; Zhu, Y | 1 |
Belhassen, B; Biton, Y; Mowaswes, M | 1 |
12 review(s) available for propafenone and quinidine
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Antiarrhythmic drug therapy. Recent advances and current status.
Topics: Adrenergic beta-Antagonists; Ajmaline; Amiodarone; Anilides; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Cardiac; Benzeneacetamides; Bepridil; Bethanidine; Bretylium Tosylate; Disopyramide; Drug Administration Schedule; Encainide; Flecainide; Heart Conduction System; Humans; Imidazoles; Lidocaine; Mexiletine; Moricizine; Myocardial Contraction; Phenothiazines; Phenytoin; Piperidines; Procainamide; Propafenone; Propiophenones; Pyrrolidines; Quinidine; Tocainide; Verapamil | 1985 |
Clinical pharmacology of old and new antiarrhythmic drugs.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anilides; Anti-Arrhythmia Agents; Benzeneacetamides; Biological Availability; Bretylium Compounds; Disopyramide; Encainide; Flecainide; Humans; Imipramine; Lidocaine; Mexiletine; Moricizine; Phenothiazines; Phenytoin; Piperidines; Procainamide; Propafenone; Propiophenones; Quinidine; Tocainide | 1985 |
Antiarrhythmic drug therapy of ventricular arrhythmias.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Bretylium Tosylate; Disopyramide; Flecainide; Heart Ventricles; Humans; Lidocaine; Mexiletine; Moricizine; Phenothiazines; Phenytoin; Piperidines; Procainamide; Propafenone; Propiophenones; Quinidine; Sotalol; Tocainide; Verapamil | 1986 |
[Electrophysiological classification of newer antiarrhythmic drugs (author's transl)].
Topics: Action Potentials; Adrenergic beta-Antagonists; Anilides; Animals; Anti-Arrhythmia Agents; Aprindine; Benzeneacetamides; Calcium; Disopyramide; Electrophysiology; Humans; Lidocaine; Mexiletine; Piperidines; Propafenone; Propiophenones; Quinidine; Sodium; Tocainide | 1980 |
Supraventricular tachycardia and pre-excitation syndromes: pharmacological therapy.
Topics: Ajmaline; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Disopyramide; Flecainide; Humans; Imidazoles; Pre-Excitation Syndromes; Propafenone; Quinidine; Sotalol; Tachycardia, Paroxysmal; Tachycardia, Supraventricular; Verapamil | 1993 |
[Antiarrhythmic treatment after reduction of atrial fibrillation by external shock].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality Therapy; Disopyramide; Electric Countershock; Flecainide; Humans; Propafenone; Quinidine; Recurrence; Sotalol | 1993 |
Is there a need for new antiarrhythmic drugs?
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Heart Conduction System; Humans; Propafenone; Quinidine; Sotalol; Torsades de Pointes | 1996 |
Cost-effective management of acute atrial fibrillation: role of rate control, spontaneous conversion, medical and direct current cardioversion, transesophageal echocardiography, and antiembolic therapy.
Topics: Algorithms; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cost-Benefit Analysis; Echocardiography, Transesophageal; Electric Countershock; Flecainide; Humans; Procainamide; Propafenone; Quinidine; Sotalol; Verapamil | 2000 |
Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Australia; Canada; Controlled Clinical Trials as Topic; Europe; Flecainide; Heart Conduction System; Heart Failure; Humans; Multicenter Studies as Topic; Myocardial Infarction; Phenethylamines; Propafenone; Quinidine; Sotalol; Sulfonamides; Survival Analysis; Therapeutic Equivalency; Treatment Outcome; United States | 2003 |
Pharmacologic and nonpharmacologic options to maintain sinus rhythm: guideline-based and new approaches.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artificial; Catheter Ablation; Flecainide; Heart Rate; Humans; Phenethylamines; Practice Guidelines as Topic; Propafenone; Quinidine; Stroke; Sulfonamides; Ventricular Dysfunction, Left | 2003 |
[Atrial flutter and fibrillation].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Calcium Channel Blockers; Catheter Ablation; Clinical Trials as Topic; Disopyramide; Electric Countershock; Electrocardiography; Emergencies; Flecainide; Heart Rate; Humans; Middle Aged; Pacemaker, Artificial; Propafenone; Quinidine; Recurrence; Sotalol; Sulfonamides; Treatment Outcome; Vasodilator Agents | 2005 |
15 trial(s) available for propafenone and quinidine
Article | Year |
---|---|
[Propafenon in ventricular arrhythmia caused by ischemic cardiopathy. Quantitative study using the Holter system].
Topics: Administration, Oral; Adult; Aged; Cardiac Complexes, Premature; Clinical Trials as Topic; Female; Heart Ventricles; Humans; Male; Middle Aged; Myocardial Infarction; Perhexiline; Placebos; Propafenone; Propiophenones; Quinidine | 1979 |
[Propafenone versus hydroquinidine in long-term pharmacological prophylaxis of atrial fibrillation].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Follow-Up Studies; Humans; Male; Middle Aged; Propafenone; Prospective Studies; Quinidine; Time Factors | 1992 |
Propafenone versus quinidine slow-release for the treatment of chronic ventricular arrhythmias.
Topics: Adult; Aged; Cardiac Complexes, Premature; Chronic Disease; Delayed-Action Preparations; Double-Blind Method; Electrocardiography, Ambulatory; Female; Heart Ventricles; Humans; Male; Metabolic Clearance Rate; Middle Aged; Propafenone; Quinidine; Tachycardia | 1990 |
Efficacy of propafenone compared with quinidine in chronic ventricular arrhythmias.
Topics: Adult; Aged; Arrhythmias, Cardiac; Clinical Trials as Topic; Double-Blind Method; Drug Tolerance; Humans; Male; Middle Aged; Propafenone; Propiophenones; Quinidine | 1985 |
[Comparison of the efficacy of propafenone and hydroquinidine in stabilized extrasystolic ventricular arrhythmia by means of dynamic electrocardiographic Holter monitoring].
Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Double-Blind Method; Drug Administration Schedule; Drug Evaluation; Electrocardiography; Female; Humans; Male; Middle Aged; Propafenone; Propiophenones; Quinidine | 1984 |
Holter monitoring comparative assessment of propafenone and dihydroquinidine efficacy in the treatment of premature ventricular beats.
Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Electrocardiography; Female; Humans; Male; Middle Aged; Monitoring, Physiologic; Propafenone; Propiophenones; Quinidine; Time Factors | 1983 |
Action of ATP on ventricular automaticity.
Topics: Adenosine Triphosphate; Adrenergic beta-Antagonists; Ajmaline; Animals; Anti-Arrhythmia Agents; Austria; Cardiac Pacing, Artificial; Drug Interactions; Emergency Medical Services; Female; Guinea Pigs; Heart Ventricles; Humans; Injections, Intravenous; Male; Propafenone; Prospective Studies; Quinidine; Tachycardia, Supraventricular; Ventricular Function; Verapamil | 1994 |
Quinidine-enhanced beta-blockade during treatment with propafenone in extensive metabolizer human subjects.
Topics: Adrenergic beta-Antagonists; Adult; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Double-Blind Method; Drug Synergism; Exercise; Female; Heart Rate; Humans; Isoproterenol; Male; Mixed Function Oxygenases; Phenotype; Propafenone; Quinidine; Stereoisomerism | 1994 |
A controlled study on oral propafenone versus digoxin plus quinidine in converting recent onset atrial fibrillation to sinus rhythm.
Topics: Administration, Oral; Adult; Aged; Atrial Fibrillation; Digoxin; Drug Combinations; Electrocardiography, Ambulatory; Female; Heart Rate; Humans; Injections, Intravenous; Male; Middle Aged; Placebos; Propafenone; Quinidine; Remission Induction; Single-Blind Method; Ventricular Function | 1994 |
[A comparison between propafenone and hydroquinidine perorally in the treatment of recent-onset atrial fibrillation].
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Evaluation; Female; Heart Rate; Humans; Male; Middle Aged; Propafenone; Quinidine; Time Factors | 1996 |
Comparisons of oral propafenone and quinidine as an initial treatment option in patients with symptomatic paroxysmal atrial fibrillation: a double-blind, randomized trial.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Atrial Fibrillation; Double-Blind Method; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Propafenone; Quinidine; Recurrence; Time Factors | 1996 |
Safety of oral propafenone in the conversion of recent onset atrial fibrillation to sinus rhythm: a prospective parallel placebo-controlled multicentre study.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Atrial Fibrillation; Digitalis Glycosides; Drug Therapy, Combination; Electrocardiography, Ambulatory; Female; Follow-Up Studies; Heart Rate; Humans; Male; Middle Aged; Propafenone; Prospective Studies; Quinidine; Safety; Treatment Outcome | 1999 |
Control of paroxysmal atrial fibrillation recurrence using combined administration of propafenone and quinidine.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Anti-Arrhythmia Agents; Atrial Fibrillation; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Female; Humans; Male; Middle Aged; Propafenone; Prospective Studies; Quinidine; Recurrence; Safety; Treatment Outcome | 2000 |
Efficacy and tolerability of oral propafenone versus quinidine in the treatment of recent onset atrial fibrillation: A randomized, prospective study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Blood Pressure; Digoxin; Drug Therapy, Combination; Electrocardiography, Ambulatory; Female; Heart Conduction System; Heart Rate; Humans; Injections, Intravenous; Male; Middle Aged; Propafenone; Prospective Studies; Quinidine; Recurrence; Time Factors; Treatment Outcome | 2009 |
Combined administration of quinidine and propafenone for atrial fibrillation: the CAQ-PAF study.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Heart Rate; Humans; Male; Middle Aged; Propafenone; Quinidine | 2012 |
68 other study(ies) available for propafenone and quinidine
Article | Year |
---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
Topics: 1-Octanol; Chromatography, High Pressure Liquid; Pharmaceutical Preparations; Solubility; Water | 2001 |
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
Topics: Blood Proteins; Chemical Phenomena; Chemistry, Physical; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding | 2002 |
Pharmacophore model of drugs involved in P-glycoprotein multidrug resistance: explanation of structural variety (hypothesis).
Topics: Adenosine Triphosphatases; Algorithms; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding Sites; Binding, Competitive; Caco-2 Cells; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fluoresceins; Humans; Ligands; Models, Molecular; Molecular Structure; Quantitative Structure-Activity Relationship; Radioligand Assay; Rhodamine 123; Stereoisomerism; Verapamil; Vinblastine | 2002 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
Topics: Animals; Antimalarials; Cluster Analysis; Computational Biology; Drug Evaluation, Preclinical; Drug Resistance; Folic Acid Antagonists; Malaria; Models, Molecular; Parasites; Plasmodium falciparum; Reproducibility of Results; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase | 2008 |
Determination of log D via automated microfluidic liquid-liquid extraction.
Topics: Automation; Biopharmaceutics; Microfluidic Analytical Techniques; Pharmacokinetics | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
Topics: Action Potentials; Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Computer Simulation; Dogs; Dose-Response Relationship, Drug; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Guinea Pigs; HEK293 Cells; Humans; Ion Channels; Kinetics; Models, Cardiovascular; NAV1.5 Voltage-Gated Sodium Channel; Patch-Clamp Techniques; Potassium Channel Blockers; Rabbits; Risk Assessment; Risk Factors; Sodium Channel Blockers; Sodium Channels; Torsades de Pointes; Transfection | 2011 |
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
Topics: Cell Line, Tumor; Cryopreservation; Female; Hepatocytes; Humans; Male; Metabolic Clearance Rate; Pharmaceutical Preparations; Predictive Value of Tests | 2012 |
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
Topics: Animals; Antimalarials; Cell Line, Tumor; Drug Discovery; Drug Evaluation, Preclinical; Drug Resistance; Erythrocytes; Humans; Imidazoles; Liver; Malaria; Mice; Mice, Inbred BALB C; Molecular Structure; Piperazines; Plasmodium; Plasmodium berghei; Plasmodium falciparum; Plasmodium yoelii; Polymorphism, Single Nucleotide; Protozoan Proteins; Random Allocation; Small Molecule Libraries; Sporozoites | 2011 |
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
Topics: Artificial Intelligence; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Computational Biology; Computer Simulation; Drugs, Investigational; Ether-A-Go-Go Potassium Channels; Expert Systems; Heart Rate; Humans; Models, Biological; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Potassium Channel Blockers; Quantitative Structure-Activity Relationship; Risk Assessment; Shaker Superfamily of Potassium Channels; Torsades de Pointes; Voltage-Gated Sodium Channel Blockers | 2012 |
Which metabolites circulate?
Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Discovery and Characterization of Fluorine-Substituted Diarylpyrimidine Derivatives as Novel HIV-1 NNRTIs with Highly Improved Resistance Profiles and Low Activity for the hERG Ion Channel.
Topics: Animals; Anti-HIV Agents; Cell Line; Crystallography, X-Ray; Drug Discovery; ERG1 Potassium Channel; Female; Fluorine; HIV Reverse Transcriptase; HIV-1; Humans; Male; Mice; Microsomes, Liver; Molecular Structure; Protein Binding; Pyrimidines; Rats, Wistar; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Thiophenes | 2020 |
Identification of C5-NH
Topics: Animals; Antiviral Agents; Biological Availability; Chick Embryo; Computer Simulation; Half-Life; Influenza A Virus, H5N1 Subtype; Mice; Molecular Docking Simulation; Molecular Dynamics Simulation; Neuraminidase; Oseltamivir; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship | 2021 |
[Anti-arrhythmia agents in heart failure].
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Cardiomyopathy, Dilated; Flecainide; Humans; Mexiletine; Middle Aged; Propafenone; Quinidine | 1992 |
[Effects of propafenone, quinidine, and their combination on ventricular fibrillation threshold in dogs].
Topics: Animals; Blood Pressure; Dogs; Drug Therapy, Combination; Female; Male; Propafenone; Quinidine; Ventricular Fibrillation | 1992 |
Is pretransplant antiarrhythmic drug therapy a risk factor?
Topics: Adolescent; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Aprindine; Cause of Death; Child; Female; Follow-Up Studies; Heart Transplantation; Humans; Male; Mexiletine; Middle Aged; Postoperative Complications; Premedication; Propafenone; Quinidine; Sotalol; Survival Rate; Transplantation, Heterotopic | 1992 |
Responsiveness of cardiac Na+ channels to antiarrhythmic drugs: the role of inactivation.
Topics: Animals; Anti-Arrhythmia Agents; Cells, Cultured; Dose-Response Relationship, Drug; Fluorides; Heart; Heart Rate; Lidocaine; Myocardium; Propafenone; Quinidine; Sodium Channels | 1991 |
Myocardial uptake and pharmacodynamics of quinidine and propafenone in isolated rabbit hearts: metabolic versus respiratory acidosis.
Topics: Acidosis; Acidosis, Respiratory; Animals; Coronary Circulation; Electrocardiography; Heart; Hydrogen-Ion Concentration; In Vitro Techniques; Male; Myocardium; Propafenone; Quinidine; Rabbits | 1991 |
Propafenone-induced torsade de pointes: cross-reactivity with quinidine.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Cross Reactions; Electrocardiography; Female; Humans; Propafenone; Quinidine; Torsades de Pointes | 1991 |
New hope in atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Propafenone; Quinidine; Sotalol | 1990 |
Phasic ion channel blockade. A kinetic model and parameter estimation procedure.
Topics: Animals; Binding Sites; Biological Transport; Electric Stimulation; In Vitro Techniques; Ion Channels; Kinetics; Lidocaine; Membrane Potentials; Muscles; Propafenone; Propiophenones; Quinidine; Solubility; Stochastic Processes | 1985 |
Genetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect.
Topics: Adult; Aged; Arrhythmias, Cardiac; Biotransformation; Electrocardiography; Female; Humans; Hydroxylation; Male; Middle Aged; Phenotype; Propafenone; Quinidine | 1989 |
[Control of the efficacy of anti-arrhythmia drug therapy with the ambulatory electrocardiogram. Proposal for a new analytical statistical model].
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrocardiography; Humans; Propafenone; Propiophenones; Prospective Studies; Quinidine; Retrospective Studies | 1985 |
[Anti-arrhythmia efficacy of propafenone per os in the prevention of paroxysmal supraventricular arrhythmia resistant to class Ia agents].
Topics: Administration, Oral; Aged; Disopyramide; Drug Evaluation; Drug Resistance; Female; Humans; Male; Middle Aged; Propafenone; Quinidine; Tachycardia, Paroxysmal; Tachycardia, Supraventricular | 1989 |
Length of excitation wave and susceptibility to reentrant atrial arrhythmias in normal conscious dogs.
Topics: Acetylcholine; Animals; Arrhythmias, Cardiac; Autonomic Nervous System; Dogs; Female; Heart Conduction System; Lidocaine; Male; Neural Conduction; Ouabain; Physical Exertion; Propafenone; Quinidine; Refractory Period, Electrophysiological; Sotalol | 1988 |
Enhanced antiarrhythmic efficacy of propafenone when used in combination with procainamide or quinidine.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Drug Synergism; Drug Therapy, Combination; Electrocardiography; Female; Humans; Male; Middle Aged; Procainamide; Propafenone; Quinidine; Stroke Volume | 1987 |
[Method for differentiating in humans the direct effects of anti-arrhythmic drugs from those mediated by the autonomic nervous system. Effects of quinidine and propafenone].
Topics: Adolescent; Adult; Aged; Atrioventricular Node; Autonomic Nervous System; Electrocardiography; Female; Heart Conduction System; Humans; Male; Middle Aged; Propafenone; Quinidine; Sinoatrial Node | 1986 |
The usefulness of electrophysiological-pharmacologic studies in the long-term therapy of paroxysmal tachycardias.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Cardiomyopathies; Chromatography, High Pressure Liquid; Disopyramide; Electric Stimulation; Electrocardiography; Female; Humans; Lidocaine; Male; Mexiletine; Middle Aged; Myocardial Infarction; Propafenone; Propiophenones; Quinidine; Tachycardia, Paroxysmal; Time Factors; Tocainide; Verapamil | 1985 |
Aggravation of ventricular arrhythmia. A drug-induced complication.
Topics: Anilides; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Cardiac; Disopyramide; Drug Evaluation; Electrocardiography; Encainide; Flecainide; Humans; Mexiletine; Piperidines; Procainamide; Propafenone; Propiophenones; Quinidine | 1985 |
[Anti-arrhythmia agents (I): Quinidine, procainamide, disopyramide, encainide, propafenone and flecainide].
Topics: Anilides; Anti-Arrhythmia Agents; Disopyramide; Encainide; Flecainide; Humans; Piperidines; Procainamide; Propafenone; Propiophenones; Quinidine | 1985 |
Use of short-term drug testing as part of a systematic approach for evaluation of antiarrhythmic drugs.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Drug Evaluation; Electric Stimulation; Humans; Monitoring, Physiologic; Procainamide; Prognosis; Propafenone; Propiophenones; Quinidine; Time Factors | 1986 |
[Effects of anti-arrhythmia agents on heart rate. Significance and importance].
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Disopyramide; Electrocardiography; Heart Conduction System; Heart Rate; Humans; Lidocaine; Propafenone; Propiophenones; Quinidine; Verapamil | 1981 |
New directions in antiarrhythmic drug therapy.
Topics: Adrenergic beta-Antagonists; Ajmaline; Amiodarone; Anilides; Anti-Arrhythmia Agents; Aprindine; Benzeneacetamides; Bepridil; Bethanidine; Bretylium Tosylate; Death, Sudden; Disopyramide; Encainide; Flecainide; Humans; Lidocaine; Mexiletine; Moricizine; Phenothiazines; Piperidines; Procainamide; Propafenone; Propiophenones; Pyrrolidines; Quinidine; Tachycardia; Tocainide; Verapamil | 1984 |
[Combinations of some anti-arrhythmia drugs].
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Digoxin; Drug Therapy, Combination; Humans; Mexiletine; Propafenone; Propiophenones; Quinidine | 1984 |
European experience with the antiarrhythmic efficacy of propafenone for supraventricular and ventricular arrhythmias.
Topics: Adolescent; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Autonomic Nervous System; Cardiac Complexes, Premature; Child; Drug Therapy, Combination; Electrocardiography; Female; Heart Ventricles; Humans; Male; Middle Aged; Propafenone; Propiophenones; Quinidine; Tachycardia; Wolff-Parkinson-White Syndrome | 1984 |
The influence of some cardiodepressant drugs on the histamine-induced restoration of contractility in potassium-depolarized heart preparations.
Topics: Animals; Calcium Channel Blockers; Depression, Chemical; Guinea Pigs; Histamine; In Vitro Techniques; Lidocaine; Male; Myocardial Contraction; Potassium; Propafenone; Propiophenones; Quinidine; Thiopental | 1981 |
Efficacy of type 1C antiarrhythmic agents for treatment of resistant atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Disopyramide; Encainide; Female; Flecainide; Heart Rate; Humans; Male; Middle Aged; Procainamide; Propafenone; Quinidine; Recurrence; Retrospective Studies | 1993 |
Chemically modified cardiac Na+ channels and their sensitivity to antiarrhythmics: is there a hidden drug receptor?
Topics: Animals; Anti-Arrhythmia Agents; Biological Transport; Cells, Cultured; Iodates; Lidocaine; Myocardium; Prajmaline; Propafenone; Quinidine; Rats; Receptors, Drug; Sodium Channels; Trypsin | 1994 |
Voltage- and time-dependent inhibitory effects on rat aortic and porcine coronary artery contraction induced by propafenone and quinidine.
Topics: Animals; Aorta, Thoracic; Calcium; Calcium Radioisotopes; Coronary Vessels; Electrophysiology; In Vitro Techniques; Male; Muscle Contraction; Muscle, Smooth, Vascular; Potassium Chloride; Propafenone; Quinidine; Rats; Rats, Sprague-Dawley; Swine; Time Factors | 1994 |
K+ channel blocking actions of flecainide compared with those of propafenone and quinidine in adult rat ventricular myocytes.
Topics: Animals; Anti-Arrhythmia Agents; Cells, Cultured; Electrophysiology; Flecainide; Heart; Heart Ventricles; Kinetics; Potassium Channels; Propafenone; Quinidine; Rats; Rats, Sprague-Dawley; Sensitivity and Specificity | 1994 |
Antiarrhythmic drugs in the management of atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Digoxin; Flecainide; Heart; Humans; Propafenone; Quinidine | 1993 |
The metabolism of aprindine in relation to the sparteine/debrisoquine polymorphism.
Topics: Aprindine; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Debrisoquin; Humans; Hydroxylation; Kinetics; Microsomes, Liver; Mixed Function Oxygenases; Polymorphism, Genetic; Propafenone; Quinidine; Sparteine | 1993 |
Quinidine versus propafenone for conversion of atrial fibrillation to sinus rhythm.
Topics: Administration, Oral; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Heart Rate; Humans; Male; Middle Aged; Propafenone; Quinidine; Treatment Outcome | 1997 |
[Can 1/1 atrial flutter be foreseen by class I anti-arrhythmics?].
Topics: Aged; Anti-Arrhythmia Agents; Atrial Flutter; Disopyramide; Electrocardiography; Female; Flecainide; Heart Conduction System; Humans; Imidazoles; Male; Middle Aged; Predictive Value of Tests; Propafenone; Quinidine; Risk Factors | 1997 |
[Pharmacological cardioversion of isolated atrial fibrillation: recovery of atrial mechanical function and correlation with duration of arrhythmia].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Function; Data Interpretation, Statistical; Echocardiography, Doppler, Pulsed; Female; Flecainide; Follow-Up Studies; Hemodynamics; Humans; Male; Middle Aged; Propafenone; Quinidine; Recurrence; Time Factors | 1997 |
Quinidine versus propafenone for conversion of atrial fibrillation to sinus rhythm.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Heart Rate; Humans; Propafenone; Quinidine; Treatment Outcome | 1998 |
Hybrid pharmacologic and ablative therapy: a novel and effective approach for the management of atrial fibrillation.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Flecainide; Follow-Up Studies; Humans; Male; Middle Aged; Propafenone; Quinidine | 1998 |
Involvement of K(+) channel in procainamide-induced relaxation of bovine tracheal smooth muscle.
Topics: Albuterol; Animals; Anti-Arrhythmia Agents; Bronchoconstrictor Agents; Bronchodilator Agents; Cattle; In Vitro Techniques; Methacholine Chloride; Mexiletine; Muscle Contraction; Muscle Relaxation; Muscle, Smooth; Potassium; Potassium Channels; Procainamide; Propafenone; Quinidine; Trachea | 2000 |
Inhibition of the current of heterologously expressed HERG potassium channels by flecainide and comparison with quinidine, propafenone and lignocaine.
Topics: Cation Transport Proteins; DNA-Binding Proteins; Dose-Response Relationship, Drug; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Flecainide; Humans; Lidocaine; Neural Inhibition; Potassium Channels; Potassium Channels, Voltage-Gated; Propafenone; Quinidine; Trans-Activators; Transcriptional Regulator ERG | 2002 |
A novel two-pore domain K+ channel, TRESK, is localized in the spinal cord.
Topics: Amino Acid Sequence; Analgesics, Non-Narcotic; Animals; Anti-Arrhythmia Agents; Arachidonic Acid; Barium; Cell Line; Cloning, Molecular; Docosahexaenoic Acids; Electrophysiology; Ethanolamines; Fatty Acids; Fatty Acids, Nonesterified; Glyburide; Humans; Hydrogen-Ion Concentration; Lidocaine; Mice; Models, Biological; Molecular Sequence Data; Patch-Clamp Techniques; Phylogeny; Potassium Channels; Propafenone; Protein Structure, Tertiary; Quinidine; Quinine; Reverse Transcriptase Polymerase Chain Reaction; Spinal Cord; Tissue Distribution; Transfection | 2003 |
A comparison of some cardiac responses to Ro 2-5803 (Rythmol), quinidine and procaine amide in laboratory animals.
Topics: Animals; Animals, Laboratory; Anti-Arrhythmia Agents; Procainamide; Propafenone; Quinidine | 1961 |
Atrial fibrillation: rate control often better than rhythm control.
Topics: Adult; Aged; Amiodarone; Anticoagulants; Arrhythmia, Sinus; Atrial Fibrillation; Canada; Disopyramide; Electric Countershock; Flecainide; Heart Rate; Humans; Netherlands; Platelet Aggregation Inhibitors; Propafenone; Quinidine; Sotalol; United States | 2004 |
[Treatment of atrial fibrillation in a Hungarian hospital department of cardiologic internal medicine at the turn of the millennium].
Topics: Acute Disease; Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiology Service, Hospital; Electric Countershock; Female; Follow-Up Studies; Hospital Departments; Humans; Hungary; Male; Middle Aged; Prajmaline; Propafenone; Quinidine; Retrospective Studies; Sotalol | 2004 |
Limitations to antiarrhythmic drug use in patients with atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Canada; Contraindications; Female; Flecainide; Humans; Male; Middle Aged; Propafenone; Quinidine; Registries; Sotalol | 2004 |
Class I antiarrhythmics inhibit Na+ absorption and Cl- secretion in rabbit descending colon epithelium.
Topics: Animals; Anti-Arrhythmia Agents; Chlorides; Colon, Descending; Electric Conductivity; Female; In Vitro Techniques; Intestinal Mucosa; Potassium; Potassium Channels, Calcium-Activated; Propafenone; Quinidine; Rabbits; Sodium | 2005 |
Usefulness of hepatocytes for evaluating the genetic polymorphism of CYP2D6 substrates.
Topics: Cells, Cultured; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Enzyme Inhibitors; Genetic Techniques; Hepatocytes; Humans; Metoprolol; Microsomes, Liver; Polymorphism, Genetic; Propafenone; Propranolol; Quinidine | 2005 |
Successful conversion of recent-onset atrial fibrillation by sequential administration of up to three antiarrhythmic drugs.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Administration Schedule; Electric Countershock; Electrocardiography; Female; Follow-Up Studies; Heart Rate; Humans; Infusions, Intravenous; Male; Middle Aged; Propafenone; Prospective Studies; Quinidine; Treatment Outcome; Young Adult | 2008 |
Is newer better? Propafenone versus quinidine for conversion of atrial fibrillation.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Atrial Fibrillation; Digoxin; Drug Therapy, Combination; Heart Conduction System; Humans; Injections, Intravenous; Propafenone; Quinidine; Recurrence; Time Factors; Treatment Outcome | 2009 |
In Silico Assessment of Class I Antiarrhythmic Drug Effects on
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Computer Simulation; Disopyramide; Heart Atria; Homeobox Protein PITX2; Homeodomain Proteins; Humans; Mice; Propafenone; Quinidine; Transcription Factors | 2021 |
Type 1 Brugada-Electrocardiogram: A Rare Presentation in a 57-Year-Old Woman with Paroxysmal Atrial Fibrillation Treated with a Therapeutic Dose of Propafenone.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Brugada Syndrome; Clinical Decision-Making; Drug Substitution; Echocardiography; Electric Countershock; Female; Humans; Middle Aged; Propafenone; Quinidine; Treatment Outcome | 2021 |